Raymond James & Associates Brainstorm Cell Therapeutics Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Raymond James & Associates holds 95,153 shares of BCLI stock, worth $120,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,153
Previous 111,285 14.5%
Holding current value
$120,844
Previous $37,000 43.24%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
SELL
$0.22 - $0.42 $3,549 - $6,775
-16,132 Reduced 14.5%
95,153 $21,000
Q2 2024

Jul 19, 2024
SELL
$0.34 - $0.74 $850 - $1,850
-2,500 Reduced 2.2%
111,285 $37,000
Q1 2024

Apr 22, 2024
SELL
$0.28 - $0.66 $560 - $1,320
-2,000 Reduced 1.73%
113,785 $63,000
Q4 2023

Jan 16, 2024
SELL
$0.15 - $0.4 $3,311 - $8,830
-22,075 Reduced 16.01%
115,785 $31,000
Q3 2023

Oct 24, 2023
SELL
$0.2 - $2.08 $5,348 - $55,625
-26,743 Reduced 16.25%
137,860 $27,000
Q2 2023

Jul 25, 2023
SELL
$2.0 - $3.2 $200 - $320
-100 Reduced 0.06%
164,603 $339,000
Q1 2023

Apr 14, 2023
SELL
$1.43 - $3.3 $68,640 - $158,400
-48,000 Reduced 22.57%
164,703 $543,000
Q4 2022

Feb 08, 2023
SELL
$1.37 - $4.42 $43,977 - $141,882
-32,100 Reduced 13.11%
212,703 $348,000
Q3 2022

Oct 25, 2022
BUY
$2.55 - $4.42 $146,370 - $253,708
57,400 Added 30.63%
244,803 $1.08 Million
Q2 2022

Aug 12, 2022
SELL
$2.71 - $3.6 $8,130 - $10,800
-3,000 Reduced 1.58%
187,403 $517,000
Q1 2022

May 11, 2022
BUY
$2.92 - $4.19 $2,628 - $3,771
900 Added 0.47%
190,403 $640,000
Q4 2021

Feb 08, 2022
SELL
$2.81 - $4.23 $28,844 - $43,420
-10,265 Reduced 5.14%
189,503 $758,000
Q3 2021

Nov 02, 2021
BUY
$3.14 - $4.09 $78 - $102
25 Added 0.01%
199,768 $659,000
Q2 2021

Aug 11, 2021
BUY
$3.01 - $4.01 $12,235 - $16,300
4,065 Added 2.08%
199,743 $759,000
Q1 2021

May 14, 2021
SELL
$3.46 - $7.88 $523,594 - $1.19 Million
-151,328 Reduced 43.61%
195,678 $749,000
Q4 2020

Feb 12, 2021
BUY
$3.99 - $17.73 $232,740 - $1.03 Million
58,331 Added 20.21%
347,006 $1.57 Million
Q3 2020

Nov 04, 2020
BUY
$11.19 - $16.92 $386,055 - $583,740
34,500 Added 13.57%
288,675 $4.88 Million
Q2 2020

Jul 28, 2020
BUY
$4.42 - $12.66 $235,254 - $673,828
53,225 Added 26.49%
254,175 $2.85 Million
Q1 2020

Apr 21, 2020
BUY
$4.01 - $8.88 $318,193 - $704,628
79,350 Added 65.25%
200,950 $932,000
Q4 2019

Feb 12, 2020
BUY
$3.62 - $4.29 $126,338 - $149,721
34,900 Added 40.25%
121,600 $520,000
Q3 2019

Nov 07, 2019
BUY
$3.54 - $4.48 $306,918 - $388,416
86,700 New
86,700 $338,000

Others Institutions Holding BCLI

# of Institutions
41
Shares Held
10.8M
Call Options Held
160K
Put Options Held
30.5K
View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

BCLI Quotes by TradingView
  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $46.3M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email